AI Engines For more Details: Perplexity Kagi Labs You
Parkinson's Disease: R(-) apomorphine hydrochloride hemihydrate is a dopamine agonist, meaning it acts similarly to dopamine in the brain. Parkinson's disease is characterized by a deficiency of dopamine, a neurotransmitter involved in motor control. This medication helps alleviate symptoms such as tremors, muscle stiffness, and difficulty with movement by stimulating dopamine receptors in the brain.
Off Episodes in Parkinson's Disease: In addition to its role in managing the overall symptoms of Parkinson's disease, R(-) apomorphine hydrochloride hemihydrate is particularly effective in treating "off" episodes, which are periods of time when standard Parkinson's medications are not providing adequate symptom control. Off episodes can be characterized by the sudden return of motor symptoms despite regular medication use.
Motor Fluctuations: Parkinson's disease is often associated with motor fluctuations, including "on-off" fluctuations and dyskinesias (involuntary movements). R(-) apomorphine hydrochloride hemihydrate can help smooth out these fluctuations and provide more consistent relief from motor symptoms.
Rescue Therapy: R(-) apomorphine hydrochloride hemihydrate is sometimes used as a rescue therapy for sudden and severe Parkinson's symptoms that do not respond well to oral medications. It is available in an injectable form for rapid administration during acute episodes of symptom worsening.
Improvement of Activities of Daily Living: By reducing motor symptoms such as bradykinesia (slowness of movement) and rigidity, R(-) apomorphine hydrochloride hemihydrate can improve the ability of individuals with Parkinson's disease to perform activities of daily living and maintain independence.
Quality of Life: The effective management of Parkinson's symptoms with R(-) apomorphine hydrochloride hemihydrate can lead to improvements in overall quality of life for patients, allowing them to participate more fully in social, occupational, and recreational activities.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 1.2 | 0 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.3 | 0.33 |
Allergic Rhinitis (Hay Fever) | 0.6 | 0.6 | |
Allergies | 0.8 | 0.3 | 1.67 |
Allergy to milk products | 0.3 | 0.3 | 0 |
Alopecia (Hair Loss) | 1 | 1 | |
Alzheimer's disease | 1.3 | 3.2 | -1.46 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.4 | 0.3 | 7 |
Ankylosing spondylitis | 1.1 | 0.8 | 0.38 |
Anorexia Nervosa | 0.3 | 1.2 | -3 |
Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
Asthma | 0 | 1.1 | 0 |
Atherosclerosis | 1.4 | -1.4 | |
Atrial fibrillation | 1.2 | 0.6 | 1 |
Autism | 1.9 | 3.9 | -1.05 |
Barrett esophagus cancer | 0.1 | 0.1 | |
Bipolar Disorder | 0.6 | 0.4 | 0.5 |
Brain Trauma | 0.6 | -0.6 | |
Carcinoma | 0.8 | 0.8 | 0 |
Celiac Disease | 0.5 | 1.5 | -2 |
Cerebral Palsy | 0.2 | 0.6 | -2 |
Chronic Fatigue Syndrome | 0.8 | 2 | -1.5 |
Chronic Kidney Disease | 0.8 | 1 | -0.25 |
Chronic Lyme | 0.6 | -0.6 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.9 | -8 |
Chronic Urticaria (Hives) | 0.1 | 1.1 | -10 |
Coagulation / Micro clot triggering bacteria | 0.3 | 0.4 | -0.33 |
Colorectal Cancer | 2 | 0 | 0 |
Constipation | 0.8 | 0.4 | 1 |
Coronary artery disease | 0 | 0.1 | 0 |
COVID-19 | 1.8 | 3.5 | -0.94 |
Crohn's Disease | 2.5 | 3.7 | -0.48 |
cystic fibrosis | 0.6 | -0.6 | |
deep vein thrombosis | 0.4 | -0.4 | |
Depression | 4.3 | 2 | 1.15 |
Eczema | 0.1 | 0.8 | -7 |
Endometriosis | 0.6 | 0.7 | -0.17 |
Eosinophilic Esophagitis | 0.1 | -0.1 | |
Epilepsy | 1.3 | 1.4 | -0.08 |
Fibromyalgia | 1 | 0.6 | 0.67 |
Functional constipation / chronic idiopathic constipation | 2.5 | 1.6 | 0.56 |
gallstone disease (gsd) | 0.4 | 0.4 | 0 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.9 | |
Generalized anxiety disorder | 0.3 | -0.3 | |
Graves' disease | 0.6 | 0.4 | 0.5 |
Halitosis | 0.3 | 0.3 | |
Hashimoto's thyroiditis | 1 | 0.3 | 2.33 |
Hidradenitis Suppurativa | 0.1 | -0.1 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.2 | 0.1 | 11 |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.3 | -0.5 |
hyperglycemia | 1.1 | -1.1 | |
Hyperlipidemia (High Blood Fats) | 0.2 | 0.2 | |
hypertension (High Blood Pressure | 0.8 | 2.7 | -2.38 |
Hypothyroidism | 0 | 0 | |
Hypoxia | 0.8 | 0.8 | |
IgA nephropathy (IgAN) | 1.3 | -1.3 | |
Inflammatory Bowel Disease | 1.1 | 4.1 | -2.73 |
Insomnia | 0.3 | 1.1 | -2.67 |
Intelligence | 0.3 | 0.3 | |
Intracranial aneurysms | 0.6 | 0.6 | |
Irritable Bowel Syndrome | 1 | 2.2 | -1.2 |
Liver Cirrhosis | 1.4 | 0.9 | 0.56 |
Long COVID | 1.6 | 2.7 | -0.69 |
Low bone mineral density | 0.9 | -0.9 | |
Lung Cancer | 0.3 | -0.3 | |
ME/CFS with IBS | 0.3 | -0.3 | |
ME/CFS without IBS | 0.1 | 1.3 | -12 |
Metabolic Syndrome | 2.1 | 3.7 | -0.76 |
Mood Disorders | 4.7 | 2 | 1.35 |
multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
Multiple Sclerosis | 0.8 | 3.9 | -3.88 |
Multiple system atrophy (MSA) | 1.4 | 1.4 | |
Neuropathy (all types) | 0.2 | 0.2 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | -1.4 | |
Obesity | 2.6 | 1.3 | 1 |
obsessive-compulsive disorder | 2.3 | 1 | 1.3 |
Osteoarthritis | 0.3 | 0.3 | |
Osteoporosis | 0.4 | 0.6 | -0.5 |
pancreatic cancer | 0.2 | 0.2 | |
Parkinson's Disease | 0.8 | 2.3 | -1.87 |
Polycystic ovary syndrome | 0.6 | 0.7 | -0.17 |
Premenstrual dysphoric disorder | 0.3 | -0.3 | |
primary biliary cholangitis | 0.3 | -0.3 | |
Psoriasis | 1 | 2.3 | -1.3 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.6 | 1.7 | -0.06 |
Rosacea | 0.2 | 0.4 | -1 |
Schizophrenia | 2 | 0.4 | 4 |
scoliosis | 1 | -1 | |
Sjögren syndrome | 0.7 | 1 | -0.43 |
Sleep Apnea | 0.7 | -0.7 | |
Stress / posttraumatic stress disorder | 1.1 | 1 | 0.1 |
Systemic Lupus Erythematosus | 1.7 | 1 | 0.7 |
Tic Disorder | 0.2 | 0.2 | |
Tourette syndrome | 0.2 | 0.3 | -0.5 |
Type 1 Diabetes | 1.2 | 0.9 | 0.33 |
Type 2 Diabetes | 2.1 | 2.6 | -0.24 |
Ulcerative colitis | 0.3 | 1.9 | -5.33 |
Unhealthy Ageing | 1.3 | 0.8 | 0.63 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.